Articles

High Pharma margins increasing the squeeze on health systems

22/02/2019

Read the article here which focusses on the cost of cancer treatment versus their manufacturing costs.

Author:

Graham Foxon, PhD, MBA
About the Author

Article Tags

Oncology Pricing

Share this article

Related articles

Webinar
05.08.2026
Decoding Germany’s SHI reform practical impl...

Germany’s SHI reform bill removes some of the most significant AMNOG restrictions introduced in 20...

Read more
Articles
22.07.2026
Defending Price Under HTA Scrutiny: Why Evidence M...

Price ambition is only defensible when the evidence can carry it  Manufacturers can no longer r...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch